Key result
Vascular remodelling may actively drive HFpEF progression and worsen diastolic dysfunction rather than act as a bystander.
Why the study?
The vascular phenotype of the established high-fat diet plus l-NAME 'two-hit' mouse model of cardiometabolic HFpEF had not been comprehensively described, limiting its application to the syndrome.
Discusses the pathophysiological role of vascular remodeling in the progression of HFpEF and the utility of the 'two-hit' mouse model to study its cardiometabolic phenotype.
Validates two-hit model for probing vascular remodelling in cardiometabolic HFpEF; leaves open translation to human disease mechanisms and therapies.
Heart failure with preserved ejection fraction (HFpEF) is a multi-organ syndrome in which symptoms of heart failure occur despite a preserved ejection fraction (≥50%).Impaired ventricular relaxation and elevated filling pressures, particularly during exertion, contribute to dyspnoea and exercise intolerance.Predisposing risk factors, including obesity, hypertension, diabetes and ageing, also promote systemic inflammation, reduced nitric oxide (NO) bioavailability and arterial stiffening, thereby linking vascular pathology to ventricular dysfunction.Vascular pathology may therefore contribute to HFpEF progression rather than develop only as a parallel consequence.Conduit artery wall thickening and fibrosis can increase afterload, whereas endothelial and vascular smooth muscle dysfunction can attenuate vasodilator and vasoconstrictor responsiveness, collectively worsening diastolic dysfunction and exercise intolerance.HFpEF is a heterogeneous syndrome with several phenotypes, one of which is a cardiometabolic form driven by metabolic and hypertensive stress.Other forms of HFpEF may be driven by ageing, cardiac amyloidosis or chronic hypertension independent of metabolic disease.Animal models therefore replicate only selected features of the human syndrome.The established high-fat diet (HFD) plus N ω -nitro-l-arginine methyl ester (l-NAME) 'two-hit' mouse model reproduces several features of cardiometabolic HFpEF, but its vascular phenotype had not been comprehensively described, limiting its application to the
No takes yet. Share an insight, caveat, or question.
Khan et al. (2026) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Vascular remodelling was evaluated. Vascular pathology and remodelling may actively contribute to HFpEF progression and worsen diastolic dysfunction, rather than developing solely as a parallel consequence of the syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: